Physician profile
Stephen N Long
NPI 1174586846
$2,415.78
in general payments reported to CMS, 2019-2025
24 companies · $17.82 in 2025
The $17.82 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $826 · 2021: $158 · 2023: $16.48 · 2024: $58.29 · 2025: $17.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $527.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $287.04 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $278.49 | 2019-2021 | |
| Pfizer INC. | $164.81 | 2019-2020 | |
| Amgen INC. | $159.87 | 2019-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $144.73 | 2019-2020 | |
| Amarin Pharma, INC. | $119.03 | 2020 | |
| Novartis Pharmaceuticals Corporation | $118.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.24 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $93.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $49.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $46.67 | 2019-2020 | |
| Lilly USA, LLC | $45.84 | 2019-2020 | |
| Abbvie INC. | $34.22 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.53 | 2019 | |
| Abbott Laboratories | $25.92 | 2021 | |
| Boston Scientific Corporation | $23.25 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.55 | 2020 | |
| Mylan Specialty L.P. | $18.26 | 2020 | |
| Genentech USA, INC. | $16.94 | 2020 | |
| Horizon Therapeutics Plc | $16.48 | 2023 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $15.81 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.